Scott Nelson Live

In this episode of, we sat down with Vijit Sabnis, co-founder and CEO of Adaptyx Biosciences.

Adaptyx is a Stanford spinout developing wearable technology for continuous molecular monitoring.

Over the past 20 years, Vijit has worked at the intersection of deep technology as an inventor, founder, and investor. Before Adaptyx, he was a Partner at Khosla Ventures and co-founded Solar Junction to commercialize high-efficiency solar cell technology. He holds a Ph.D. in Electrical Engineering from Stanford.

In this interview, Vijit discusses how to recognize when a scientific idea is worth building a company around, how to build startup-style learning cycles when spinning technology out of academia, and designing products that are easy for clinicians and consumers to adopt. 

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Bob Paulson, President and CEO of Sonex Health. 

Sonex’s UltraGuideCTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia, expanding patient access and reducing the cost of care.

Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical.

In this interview, Bob explains how to build a reimbursement strategy before your first clinical study, drive physician adoption when introducing a new care pathway, and raise capital aligned with value inflection points. 

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Dr. Sudhir Srivastava, founder, chairman, and CEO of SS Innovations (Nasdaq: SSII). 

The company’s SSi Mantra surgical robotic system supports a variety of surgical robotic procedures, including cardiac surgery. 

Sudhir brings more than three decades of experience in minimally invasive and robotic cardiac interventions, having served as Director of Robotic Cardiac Surgery at the University of Chicago and founder of the International College of Robotic Surgery. A pioneer in the field, Sudhir has performed more than 1,400 robotic procedures, including over 750 beating-heart totally endoscopic coronary artery bypass (TECAB) surgeries.

In this interview, Sudhir discusses what it takes to democratize robotic surgery beyond affordability, how SS Innovations built teleproctoring, telesurgery, and the supporting infrastructure for its robotic platform, and his milestone-based approach to financing a capital-intensive medtech company. 

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Aditya Rajagopal, co-founder and CEO of Esperto Medical.

Esperto is a Caltech spin-out utilizing compressed sensing technology with ultrasound to continuously and non-invasively measure blood pressure.

Before Esperto, Aditya co-founded ChromaCode, a molecular diagnostics company, and was a researcher at Google[x], where he worked on novel medical imaging methods. Aditya also serves as part-time faculty at Caltech and USC, and holds BS, MS, and PhD degrees in Electrical Engineering from Caltech. 

In this interview, Aditya discusses why great science doesn’t necessarily make great companies, what it takes to win as a fast-follower in medtech, and how to sequence a platform technology without spreading resources too thin.

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Eric Kau, co-founder and CEO of Climatic.

Climatic is commercializing L Max, a daily inhaled system that proactively supports lung function.

Before Climatic, Eric served as COO of Seed Health and was part of the foundational team at Chewy. Earlier in his career, Eric held growth and operational leadership roles across consumer, wellness, and e-commerce businesses, including Amazon, BoxyCharm, Target, and Best Buy. 

In this interview, Eric discusses what it takes to build a consumer category that doesn’t yet exist, how Climatic approached clinical validation and consumer education simultaneously, and how early user behavior helped identify the company’s strongest initial customer cohorts.

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Kara Egan, founder and CEO of Teal Health.

Teal Health is the company behind the first FDA-authorized at-home cervical cancer screening wand.

Before founding Teal, Kara worked in healthcare and software investing at .406 Ventures and Emergence Capital, and held product and marketing roles at Zendesk and Stitch Labs.  

In this interview, Kara discusses building support and follow-up into at-home screening, how Teal expanded its comparative clinical study to support broader market adoption, and how healthcare incentives, reimbursement, and institutional trust shape new care models.

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Karthik Ganesh, CEO of OnMed.

OnMed is the healthcare technology company behind OnMed CareStation, a “Clinic-in-a-Box” designed to expand access to primary and urgent care. 

Before OnMed, Karthik served as CEO of EmpiRx Health, leading the company through rapid growth and a successful private equity transaction in 2021. Throughout his career, he’s held leadership roles at QualCare, CareAllies, and Aetna, and advised healthcare organizations through Deloitte and EY.

In this interview, Karthik discusses why hybrid care models still require a human touch, how enterprise healthcare buyers evaluate value propositions differently, why brand and culture should shape execution early, and how operating under constraints can sharpen innovation.

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Dr. Connie Lehman, founder and CEO of Clairity.

Clairity is the first FDA-authorized AI platform that predicts a woman's five-year risk of developing breast cancer using only a routine screening mammogram.

A physician scientist with over 300 peer-reviewed publications, Connie is a Professor of Radiology at Harvard Medical School and Breast Imaging Specialist at Massachusetts General Brigham (on leave). She holds an MD and PhD from Yale and was named to Forbes' 50 Over 50 Innovators and TIME 100 World’s Most Influential Leaders in Health.

In this interview, Connie discusses her experience translating academic research into a commercially viable startup, the massive undertaking of generating clinical evidence when you’re creating a new category, and how Clairity is approaching adoption on two fronts: fitting into physician workflows and building access pathways for patients.

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Antony Odell, co-founder and CEO of Echopoint Medical.

Echopoint is a London-based UCL spinout developing iKOr, an optical microcatheter for coronary diagnostics.

Antony brings over 30 years of medtech experience across Johnson & Johnson, Fresenius, and Stryker, before transitioning into startups as CEO of Tayside Flow Technologies and Tissue Regenix. He holds a BSc in Physiology and Biochemistry.

In this interview, Antony discusses translating academic IP into a commercial device, choosing early clinical sites to balance speed and learning, managing non-dilutive funding as a long-term discipline, and outlines the most important responsibilities of an early-stage medtech CEO.

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Kurt Jacobus, co-founder and CEO of restor3d.

restor3d provides patient-specific orthopedic implants using 3D printing and advanced software.

Kurt has over two decades of experience in medtech entrepreneurship, including successful exits to Enovis and NuVasive. Prior to his career in medical devices, Kurt was a consultant at McKinsey & Company. He holds a PhD in Mechanical Engineering and is an Adjunct Professor at Georgia Tech. 

In this interview, Kurt discusses how restor3d used the FDA's 520(b) pathway to generate revenue and regulatory proof simultaneously, why self-regulating beyond FDA requirements makes submissions a competitive barrier, and how to approach investor relationships and board construction with long-term thinking.

KEY MOMENTS FROM THE INTERVIEW